Browsing Tag

Calithera

Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical…

Eli Pacheco Jul 14, 2022 0

-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1…

Health

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of…

Eli Pacheco Jun 24, 2022 0

-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes -- Study will evaluate SYK inhibitor both in patients with wild-type…

Health

Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of…

Eli Pacheco Mar 30, 2022 0

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced…

Health

Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4…

Eli Pacheco Mar 8, 2022 0

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced…